Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours
Treatment with paltusotine did not significantly reduce radioligand binding of <sup>18</sup>F-SiTATE <i>in vitro</i>, indicating no influence on SSTR2 targeting. This might enable a continuation of somatostatin receptor analogue therapy with paltusotine during PRRT, potentially improving symptom control in GEP-NET patients with the carcinoid syndrome.
Authors
- Umberto Macciò (ORCID: https://orcid.org/0000-0003-3253-3787)
- Е.В. Кузьменко
- Felix Beuschlein (ORCID: https://orcid.org/0000-0001-7826-3984)
- Martín Reincke (ORCID: https://orcid.org/0000-0002-9817-9875)
- Christoph Josef Auernhammer (ORCID: https://orcid.org/0000-0001-8087-3722)
- Rudolf Alexander Werner (ORCID: https://orcid.org/0000-0003-3372-6046)
- José Oberholzer (ORCID: https://orcid.org/0000-0002-1069-2501)
- Ashley Barry Grossman (ORCID: https://orcid.org/0000-0003-1176-6186)
- Constanze Hantel (ORCID: https://orcid.org/0009-0000-8906-2563)
- Diana Vetter (ORCID: https://orcid.org/0000-0001-9622-0988)
- Katharina Wang (ORCID: https://orcid.org/0000-0002-7795-1395)
- Karel Pacák (ORCID: https://orcid.org/0000-0002-3541-3767)
- Thomas Knösel (ORCID: https://orcid.org/0000-0002-1822-0197)
- Svenja Nölting (ORCID: https://orcid.org/0000-0002-7064-590X)
- Astrid Reul
- Lea Peischer
- Maximilian Hungbauer
- Simon Lindner (ORCID: https://orcid.org/0009-0007-4379-4436)
- Kathrin Zitzmann (ORCID: https://orcid.org/0009-0001-2341-3161)
- Mathias J. Zacherl
- Julian Maurer
- Julia Hamati
Institutions
- University of Zurich (CH)
- The Royal Free Hospital (GB)
- LMU Klinikum (DE)
- University of Oxford (GB)
- European Neuroendocrine Tumor Society (DE)
- Akcent International House Prague (CZ)
- University Hospital of Zurich (CH)
- University Hospital Carl Gustav Carus (DE)
- University College London (GB)
- Palacký University Olomouc (CZ)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-25-0041
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00